Aquestive Therapeutics, Inc. Payments of Financing Costs
Aquestive Therapeutics, Inc. (AQST) reported Payments of Financing Costs of $3.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-08-11
- Aquestive Therapeutics, Inc. payments of financing costs for the quarter ending 2025-09-30 was $21.00K, a 162.50% increase year-over-year.
- Aquestive Therapeutics, Inc. payments of financing costs for the quarter ending 2025-06-30 was -$6.00K, a 220.00% decline year-over-year.
- Aquestive Therapeutics, Inc. payments of financing costs for the quarter ending 2025-03-31 was $6.00K, a 20.00% increase year-over-year.
- Aquestive Therapeutics, Inc. payments of financing costs for the quarter ending 2024-12-31 was -$18.00K.
- Aquestive Therapeutics, Inc. payments of financing costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. payments of financing costs for fiscal 2023 was $4.64M.
- Aquestive Therapeutics, Inc. payments of financing costs for fiscal 2022 was $0.00.
- Aquestive Therapeutics, Inc. payments of financing costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Payments of Financing Costs | Payments of Financing Costs 3 month | Payments of Financing Costs 3 month as first filed | Payments of Financing Costs 6 month | Payments of Financing Costs 6 month as first filed | Payments of Financing Costs 9 month | Payments of Financing Costs 9 month as first filed | Payments of Financing Costs 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.47M 10-Q · filed 2026-08-11 | |||||||
| 2025-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $15.00K derived: sum of 2 quarters · filed 2026-08-11 | $21.00K 10-Q · filed 2025-11-05 | $3.00K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $14.00K 10-Q · filed 2025-08-11 | -$18.00K derived: sum of 3 quarters · filed 2026-08-11 | -$10.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $6.00K 10-Q · filed 2025-05-12 | -$12.00K derived: sum of 2 quarters · filed 2025-05-12 | -$4.00K derived: sum of 3 quarters · filed 2025-11-05 | $1.00K derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$10.00K derived: sum of 2 quarters · filed 2025-11-05 | -$5.00K derived: sum of 3 quarters · filed 2025-11-05 | $0.00 10-K · filed 2025-03-05 | ||||
| 2024-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.00K derived: sum of 2 quarters · filed 2025-11-05 | $18.00K 10-Q · filed 2025-11-05 | -$7.89M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $10.00K 10-Q · filed 2025-08-11 | -$7.89M derived: sum of 3 quarters · filed 2025-08-11 | -$7.89M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $5.00K 10-Q · filed 2025-05-12 | -$7.90M derived: sum of 2 quarters · filed 2025-05-12 | -$7.89M derived: sum of 3 quarters · filed 2025-05-12 | -$4.44M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | -$7.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$7.90M derived: sum of 2 quarters · filed 2025-03-05 | -$4.44M derived: sum of 3 quarters · filed 2025-03-05 | $4.64M 10-K · filed 2025-03-05 | ||||
| 2023-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $3.46M derived: sum of 2 quarters · filed 2024-11-04 | $12.55M 10-Q · filed 2024-11-04 | $12.55M derived: sum of 4 quarters · filed 2024-11-04 | ||||
| 2023-06-30 | $3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $12.54M 10-Q · filed 2024-08-06 | $12.54M derived: sum of 3 quarters · filed 2024-08-06 | $12.54M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $9.09M 10-Q · filed 2024-05-07 | $2.91M 10-Q · filed 2023-05-02 | $9.09M derived: sum of 2 quarters · filed 2024-05-07 | $9.09M derived: sum of 3 quarters · filed 2024-05-07 | $6.18M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | -$2.91M derived: sum of 3 quarters · filed 2024-03-05 | $0.00 10-K · filed 2024-03-05 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$2.91M derived: sum of 2 quarters · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 | $2.91M 10-Q · filed 2022-11-01 | -$2.91M derived: sum of 4 quarters · filed 2023-11-06 | |||
| 2022-06-30 | -$2.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $2.91M 10-Q · filed 2022-08-02 | -$2.91M derived: sum of 3 quarters · filed 2023-08-07 | -$2.91M derived: sum of 4 quarters · filed 2023-08-07 | |||
| 2022-03-31 | $2.91M 10-Q · filed 2022-05-04 | $0.00 derived: sum of 2 quarters · filed 2022-05-04 | $0.00 derived: sum of 3 quarters · filed 2022-05-04 | |||||
| 2021-12-31 | -$2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$2.91M derived: sum of 2 quarters · filed 2022-03-08 | $0.00 10-K · filed 2022-03-08 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $2.91M 10-Q · filed 2021-11-02 | ||||||
| 2021-06-30 | $2.91M 10-Q · filed 2021-08-03 | |||||||
| 2020-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $2.91M 10-K · filed 2022-03-08 | ||||||
| 2020-11-03 | $2.91M 10-K · filed 2023-03-31 | |||||||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-04 | |||||||
| 2019-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $3.95M 10-K · filed 2021-03-09 | ||||||
| 2019-09-30 | $3.92M 10-Q · filed 2020-11-04 | |||||||
| 2018-12-31 | $4.77M 10-K · filed 2020-03-11 | |||||||
| 2018-06-30 | $1.53M 10-Q · filed 2018-09-04 | |||||||
| 2017-12-31 | $610.00K 10-K · filed 2019-03-14 | |||||||
| 2017-06-30 | $3.00K 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |